FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2489722909> ?p ?o ?g. }

• W2489722909 endingPage "429" @default.
• W2489722909 startingPage "423" @default.
• W2489722909 abstract "Hypothalamic hamartoma (HH) with gelastic epilepsy is a well-recognized drug-resistant epilepsy syndrome of early life.1Berkovic S.F. Arzimanoglou A. Kuzniecky R. Harvey A.S. Palmini A. Andermann F. Hypothalamic hamartoma and seizures: a treatable epileptic encephalopathy.Epilepsia. 2003; 44: 969-973Crossref PubMed Scopus (139) Google Scholar Surgical resection allows limited access to the small deep-seated lesions that cause the disease. Here, we report the results of a search for somatic mutations in paired hamartoma- and leukocyte-derived DNA samples from 38 individuals which we conducted by using whole-exome sequencing (WES), chromosomal microarray (CMA), and targeted resequencing (TRS) of candidate genes. Somatic mutations were identified in genes involving regulation of the sonic hedgehog (Shh) pathway in 14/38 individuals (37%). Three individuals had somatic mutations in PRKACA, which encodes a cAMP-dependent protein kinase that acts as a repressor protein in the Shh pathway, and four subjects had somatic mutations in GLI3, an Shh pathway gene associated with HH. In seven other individuals, we identified two recurrent and three single brain-tissue-specific, large copy-number or loss-of-heterozygosity (LOH) variants involving multiple Shh genes, as well as other genes without an obvious biological link to the Shh pathway. The Shh pathway genes in these large somatic lesions include the ligand itself (SHH and IHH), the receptor SMO, and several other Shh downstream pathway members, including CREBBP and GLI2. Taken together, our data implicate perturbation of the Shh pathway in at least 37% of individuals with the HH epilepsy syndrome, consistent with the concept of a developmental pathway brain disease. Hypothalamic hamartoma (HH) with gelastic epilepsy is a well-recognized drug-resistant epilepsy syndrome of early life.1Berkovic S.F. Arzimanoglou A. Kuzniecky R. Harvey A.S. Palmini A. Andermann F. Hypothalamic hamartoma and seizures: a treatable epileptic encephalopathy.Epilepsia. 2003; 44: 969-973Crossref PubMed Scopus (139) Google Scholar Surgical resection allows limited access to the small deep-seated lesions that cause the disease. Here, we report the results of a search for somatic mutations in paired hamartoma- and leukocyte-derived DNA samples from 38 individuals which we conducted by using whole-exome sequencing (WES), chromosomal microarray (CMA), and targeted resequencing (TRS) of candidate genes. Somatic mutations were identified in genes involving regulation of the sonic hedgehog (Shh) pathway in 14/38 individuals (37%). Three individuals had somatic mutations in PRKACA, which encodes a cAMP-dependent protein kinase that acts as a repressor protein in the Shh pathway, and four subjects had somatic mutations in GLI3, an Shh pathway gene associated with HH. In seven other individuals, we identified two recurrent and three single brain-tissue-specific, large copy-number or loss-of-heterozygosity (LOH) variants involving multiple Shh genes, as well as other genes without an obvious biological link to the Shh pathway. The Shh pathway genes in these large somatic lesions include the ligand itself (SHH and IHH), the receptor SMO, and several other Shh downstream pathway members, including CREBBP and GLI2. Taken together, our data implicate perturbation of the Shh pathway in at least 37% of individuals with the HH epilepsy syndrome, consistent with the concept of a developmental pathway brain disease. Some brain malformation syndromes are due to inherited germline mutations or germline or post-zygotic de novo mutations (reviewed in Poduri et al.2Poduri A. Evrony G.D. Cai X. Walsh C.A. Somatic mutation, genomic variation, and neurological disease.Science. 2013; 341: 1237758Crossref PubMed Scopus (407) Google Scholar). Yet the cause of most brain malformations, with their frequent consequences of refractory epilepsy and intellectual disability, remains unknown. Recently, exome sequencing studies in privileged situations in which brain tissue is available have highlighted the role of somatic mutations confined to the brain. For example, somatic mutations in mTOR pathway genes (e.g., PIK3CA [MIM: 171834], AKT3 [MIM: 611223], and MTOR [MIM: 601231]) have been found to be important for a variety of malformations of cortical development, ranging from large hemispheric malformations to small focal cortical dysplasias.3Lee J.H. Huynh M. Silhavy J.L. Kim S. Dixon-Salazar T. Heiberg A. Scott E. Bafna V. Hill K.J. Collazo A. et al.De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Nat. Genet. 2012; 44: 941-945Crossref PubMed Scopus (491) Google Scholar, 4Lim J.S. Kim W.I. Kang H.C. Kim S.H. Park A.H. Park E.K. Cho Y.W. Kim S. Kim H.M. Kim J.A. et al.Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.Nat. Med. 2015; 21: 395-400Crossref PubMed Scopus (320) Google Scholar, 5Nakashima M. Saitsu H. Takei N. Tohyama J. Kato M. Kitaura H. Shiina M. Shirozu H. Masuda H. Watanabe K. et al.Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.Ann. Neurol. 2015; 78: 375-386Crossref PubMed Scopus (135) Google Scholar, 6Poduri A. Evrony G.D. Cai X. Elhosary P.C. Beroukhim R. Lehtinen M.K. Hills L.B. Heinzen E.L. Hill A. Hill R.S. et al.Somatic activation of AKT3 causes hemispheric developmental brain malformations.Neuron. 2012; 74: 41-48Abstract Full Text Full Text PDF PubMed Scopus (345) Google Scholar Outside these rare disorders, the role of somatic mutations in drug-resistant epilepsies is largely unexplored.7Helbig I. Lowenstein D.H. Genetics of the epilepsies: where are we and where are we going?.Curr. Opin. Neurol. 2013; 26: 179-185Crossref PubMed Scopus (69) Google Scholar, 8Lindhout D. Somatic mosaicism as a basic epileptogenic mechanism?.Brain. 2008; 131: 900-901Crossref PubMed Scopus (20) Google Scholar Because the very rare dominant disorder of Pallister-Hall syndrome (MIM: 146510), comprising hypothalamic hamartomas (HHs [MIM: 241800]) and various other congenital anomalies, is due to germline truncation mutations in GLI3 (MIM: 165240),9Kang S. Graham Jr., J.M. Olney A.H. Biesecker L.G. GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome.Nat. Genet. 1997; 15: 266-268Crossref PubMed Scopus (407) Google Scholar we previously searched for somatic GLI3 mutations in hamartoma tissue. We established that a few cases have de novo somatic point mutations or copy-number variants (CNVs) at this locus,10Wallace R.H. Freeman J.L. Shouri M.R. Izzillo P.A. Rosenfeld J.V. Mulley J.C. Harvey A.S. Berkovic S.F. Somatic mutations in GLI3 can cause hypothalamic hamartoma and gelastic seizures.Neurology. 2008; 70: 653-655Crossref PubMed Scopus (17) Google Scholar, 11Craig D.W. Itty A. Panganiban C. Szelinger S. Kruer M.C. Sekar A. Reiman D. Narayanan V. Stephan D.A. Kerrigan J.F. Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.Am. J. Hum. Genet. 2008; 82: 366-374Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar a finding that has now been independently confirmed.12Saitsu H. Sonoda M. Higashijima T. Shirozu H. Masuda H. Tohyama J. Kato M. Nakashima M. Tsurusaki Y. Mizuguchi T. et al.Somatic mutations in GLI3 and OFD1 involved in sonic hedgehog signaling cause hypothalamic hamartoma.Ann Clin Transl Neurol Epub. 2016; (Mar 24th)Google Scholar These early observations motivated a genome-wide search for somatic mutations via our unique access to hamartoma tissue and venous blood from individuals with HH. Surgical removal of these lesions was once regarded as hazardous. The development of innovative surgical techniques13Rosenfeld J.V. Harvey A.S. Wrennall J. Zacharin M. Berkovic S.F. Transcallosal resection of hypothalamic hamartomas, with control of seizures, in children with gelastic epilepsy.Neurosurgery. 2001; 48: 108-118Crossref PubMed Google Scholar led to a relatively large series of this rare disorder being available at The Royal Children’s Hospital and The Barrow Institute. Herein, we studied DNA extracted according to standard protocols from freshly frozen or formalin-fixed paraffin-embedded hamartoma tissue and leukocytes of 38 individuals with HH to identify somatic mutations. The human research ethics committees of the Austin Hospital and The Royal Children’s Hospital in Melbourne and the institutional review board of St. Joseph’s Hospital and Medical Center in Phoenix approved this study. Informed consent was obtained from affected individuals or their parents or legal guardians in the case of minors, those with intellectual disability, or deceased individuals. There were 11 females and 27 males, all with intractable epilepsy (Table S1). Epilepsy began in the first year of life in 30/38 of these indivdiuals, and all had gelastic (laughing) seizures. Additional features included intellectual disability in 24 individuals and central precocious puberty in 14 individuals; however, none had additional syndromic features of digital, oro-facial abnormalities or visceral malformations and none had a family history of HH. Samples were subjected to whole-exome sequencing (WES) as described previously14EuroEPINOMICS-RES ConsortiumEpilepsy Phenome/Genome ProjectEpi4K ConsortiumDe novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies.Am. J. Hum. Genet. 2014; 95: 360-370Abstract Full Text Full Text PDF PubMed Scopus (315) Google Scholar, 15Epi4K Consortium; Epilepsy Phenome/Genome ProjectDe novo mutations in epileptic encephalopathies.Nature. 2013; 501: 217-221Crossref PubMed Scopus (1092) Google Scholar, chromosomal microarray (CMA; Figure S1), and targeted resequencing (TRS) of 50 genes in the Shh pathway (Roche SeqCap EZ); the methodology selected depended on the quality and quantity of DNA from the brain samples. Due to limited DNA, nine hamartoma DNA samples were whole-genome amplified (QIAGEN Repli-g Single Cell) prior to WES. Our first experiment was to subject a subset of paired DNA samples from hamartomas and leukocytes to WES (n = 15). Somatic single-nucleotide variants (sSNVs) were called from the aligned BAM files in both VarScan-2 and Mutect.16Cibulskis K. Lawrence M.S. Carter S.L. Sivachenko A. Jaffe D. Sougnez C. Gabriel S. Meyerson M. Lander E.S. Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.Nat. Biotechnol. 2013; 31: 213-219Crossref PubMed Scopus (2909) Google Scholar VarScan-2 was used to call somatic insertion-deletion variants (sindels).17Koboldt D.C. Zhang Q. Larson D.E. Shen D. McLellan M.D. Lin L. Miller C.A. Mardis E.R. Ding L. Wilson R.K. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.Genome Res. 2012; 22: 568-576Crossref PubMed Scopus (2962) Google Scholar sSNVs were removed from consideration if they were called in regions where there was less than 10-fold sequencing coverage in either the hamartoma or leukocytes, if the variant was present in less than three sequencing reads in the hamartoma, and if the variant was present in more than 5% of reads from leukocytes. Sindels with strand bias were filtered out with the Phred-scaled strand bias score. A somatic variant was classified as a candidate variant if it was predicted to change or truncate the amino acid sequence (Ensembl Variant Effect Predictor); this included missense (possibly- or probably-damaging or unknown according to PolyPhen-2), nonsense (frameshift and stop), and splice-site variants that were not present in controls sequenced in house (Institute for Genomic Medicine), in the Exome Variant Server (EVS), or in the Exome Aggregation Consortium (ExAC) database. The number of sSNVs and sindels detected in surgically resected tissue from the individuals with HH varied, despite high average coverage across exons (∼100 fold; Table S2). A total of 374 sSNVs were called on average per sample, including 12 candidate variants on average per sample (Tables S2 and S3). An average of 254 sindels were detected per sample, of which four on average per sample were candidate variants (Tables S2 and S3). Not unexpectedly, the nine samples for which the hamartoma DNA was whole-genome amplified due to very limited amounts of starting material prior to the preparation of the sequencing library produced larger numbers of sSNVs and sindels, most likely due to amplification artifacts. Among unamplified samples, 175 ± 51 and 186 ± 36 sSNVs and sindels, respectively, were called, versus 507 ± 479 sSNVs and 300 ± 211 sindels in the amplified samples (Table S2). We performed a pathway analysis to determine whether candidate variants detected through WES were statistically significantly enriched in the Shh signaling pathway or any other Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (n = 301)18Kanehisa M. Goto S. KEGG: kyoto encyclopedia of genes and genomes.Nucleic Acids Res. 2000; 28: 27-30Crossref PubMed Scopus (18116) Google Scholar by comparing the observed per base rate of candidate variants within and outside the pathway for each individual to the null expectation, estimated from the total number of candidate variants observed in the exome, the relative proportion of exonic bases within and outside the pathway that were sufficiently sequenced in the hamartoma and leukocyte DNA to call a candidate variant, and the relative mutability of the sequences within and outside of the pathway (see Supplemental Note). Two pathways of the 301 tested were enriched for candidate variants: the Shh pathway (p = 3 × 10−5) and the salivary secretion pathway (p = 0.017). We next evaluated whether any genes in these two pathways were significantly enriched for candidate variants. GLI3 and PRKACA ([MIM: 601639], see Supplemental Note), both of which are involved in the Shh signaling pathway (defined by KEGG), were found to have two and three candidate variants, respectively, all in different individuals (Table 1). The uncorrected p values of seeing two and three candidate variants in GLI3 and PRKACA were 0.0025 and 2 × 10−7, respectively. Correcting for the ∼18,000 protein-coding genes genome wide, PRKACA is significantly enriched for candidate variants, implicating PRKACA as a HH-associated gene. We note that PRKACA encodes a protein that is named in both the Shh signaling and salivary secretion pathways (defined by KEGG). Given the existing evidence for the Shh signaling pathway in HH pathophysiology,10Wallace R.H. Freeman J.L. Shouri M.R. Izzillo P.A. Rosenfeld J.V. Mulley J.C. Harvey A.S. Berkovic S.F. Somatic mutations in GLI3 can cause hypothalamic hamartoma and gelastic seizures.Neurology. 2008; 70: 653-655Crossref PubMed Scopus (17) Google Scholar, 11Craig D.W. Itty A. Panganiban C. Szelinger S. Kruer M.C. Sekar A. Reiman D. Narayanan V. Stephan D.A. Kerrigan J.F. Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.Am. J. Hum. Genet. 2008; 82: 366-374Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar, 12Saitsu H. Sonoda M. Higashijima T. Shirozu H. Masuda H. Tohyama J. Kato M. Nakashima M. Tsurusaki Y. Mizuguchi T. et al.Somatic mutations in GLI3 and OFD1 involved in sonic hedgehog signaling cause hypothalamic hamartoma.Ann Clin Transl Neurol Epub. 2016; (Mar 24th)Google Scholar we believe somatic variants in PRKACA lead to HH through disruption of the Shh signaling pathway. In addition to PRKACA, one additional gene, ZNF362, harboring a recurrent somatic mutation found in three individuals (Table S3), was found to be significantly enriched genome wide for candidate variants. These variants were found to be selectively observed in DNA specimens that were exome sequenced after whole-genome amplification in this study and in DNA from 12 out of 20 other individuals (without HH) that were also sequenced after whole-genome amplification as part of other genetic studies and therefore were not pursued further.Table 1Study Participants with Confirmed Somatic Mutations in or Linked to the Shh PathwaySubjectGenomic Analysis Method(s)Annotation of Candidate MutationsShh Gene(s) (KEGG)VAF BrainVAF BloodMethod of DetectionWESCMATRShht25086×−−c.984dupT (p.Asp329Ter) [GenBank: NM_002730.3]PRKACA25%0.5%WES, confirmed by Sangerhht238a×−−c.983_984delTT (p.Phe328Ter) [GenBank: NM_002730.3]PRKACA23%0%WES, confirmed by Sangerhht1198c××−chr7q LOH (chr7:58,814,064–159,138,663)SHH, SMO, WNT16, WNT2NANAWES, confirmed by CMAhht735×××chr16p LOH (chr16:0–31,543,619)CREBBPaNANAWES, confirmed by CMAhht209×−−c.2989dupG (p.Ala997GlyfsTer87) [GenBank: NM_000168.5]GLI357%0%WES, confirmed by Sangerhht26139×−−c.3442C>T (p.Gln1148Ter) [GenBank: NM_000168.5]GLI324%0%WES, confirmed by Sangerhht880−×−chr2q12.1–q37.3 LOH (chr2:103,856,408–243,199,373)GLI2, IHH, LRP2, STK36, WNT10A, WNT6NANACMAhht953−×−chr14q11.2–q32.33 LOH (chr14:24,419,118–106,072,470)BMP4, AKT1NANACMAhht25057−×−chr16p11.2–p13.3 LOH (chr16:0–31543619)CREBBPaTranscriptional regulator of the Shh pathway.NANACMAhht25063−×−chr7p22.1–q36.3 CNG, CNL (chr7:986211–60069242, 58814064–159138663)GLI3, SHH, SMO, WNT16, WNT2NANACMAhht25094−×−chr11q12.3–q25 LOH (chr11:64879188–135006516)WNT11NANACMAhht25077−××c.3172C>T (p.Arg1058Ter) [GenBank: NM_000168.5]GLI318%0%TRS, confirmed by Sangerhht31536−××c.2071C>T (p.Gln691Ter) [GenBank: NM_000168.5]GLI337%0.8%TRS, confirmed by Sangerhht25085−−−c.226-231dup (p.Asp76_Lys77dup) [GenBank: NM_002730.3]PRKACAbIdentified by Sanger sequencing.––SangerShh, sonic hedgehog; VAF, variant allele frequency; LOH, loss of heterozygosity (might be copy-number neutral LOH); CNG, copy-number gain; CNL, copy-number loss; WES, whole-exome sequencing; CMA, chromosomal microarray; TRS, targeted resequencing; ×, used; −, not used; NA, not applicable. All coordinates correspond to the UCSC Genome Browser reference genome (GRCH37/hg19).a Transcriptional regulator of the Shh pathway.b Identified by Sanger sequencing. Open table in a new tab Shh, sonic hedgehog; VAF, variant allele frequency; LOH, loss of heterozygosity (might be copy-number neutral LOH); CNG, copy-number gain; CNL, copy-number loss; WES, whole-exome sequencing; CMA, chromosomal microarray; TRS, targeted resequencing; ×, used; −, not used; NA, not applicable. All coordinates correspond to the UCSC Genome Browser reference genome (GRCH37/hg19). To screen for additional somatic mutations in PRKACA and GLI3, we then performed Sanger sequencing of the protein-coding exons by using standard protocols in hamartoma and blood DNA of 20 individuals with HH from our cohort that had not already been subjected to WES and identified a frameshift indel in PRKACA in an additional individual (hht25085; Table 1). In addition to sSNVs and sindels, two large somatic loss-of-heterozygosity (sLOH) events were observed in the 15 samples analyzed by exome sequencing (Figure S2). One individual had sLOH across the p arm of chromosome 16, and another had sLOH across the q arm of chromosome 7 (Table 1; Figure 1). Interestingly, both regions contain genes connected to the Shh pathway; both SHH (MIM: 600725) and SMO (MIM: 601500), as well as WNT16 (MIM: 606267) and WNT2 (MIM: 147870), are located in the sLOH region on the q arm of chromosome 7; a transcriptional co-activator of the pathway, CREBBP (MIM: 600140), is located in the sLOH region on chromosome 16p. Because four of the five candidate variants were putatively protein-truncating mutations and because we observed two large LOH events with WES, we then used CMA to screen for somatic genomic deletions and other CNVs genome wide in 28 HH cases with adequate tumor DNA. We included the two exome-sequenced samples harboring large LOH regions on chromosomes 7q or 16p to confirm the detected somatic events. Analysis revealed a large somatic event in seven of the 28 individuals with HH, including confirmation of the two LOH lesions found by WES (Table 1; Figures S1 and S2). The lesions at 7q and 16p deletions were recurrent, given that one additional individual was found with copy-number neutral LOH (CNNLOH) events at each of these loci (Table 1). Three non-recurrent CNV or LOH events were also identified. One was found on chromosome 2q and included the Shh and/or WNT pathway members IHH (MIM: 600726), STK36 (MIM: 607652), GLI2 (MIM: 165230), LRP2 (MIM: 600073), WNT10A (MIM: 606268), and WNT6 (MIM: 604663). The second was on chromosome 14q and encompassed BMP4 (MIM: 112262) and AKT1 (MIM: 164730), a gene encoding a protein known to interact with the Shh pathway19Kebenko M. Drenckhan A. Gros S.J. Jücker M. Grabinski N. Ewald F. Grottke A. Schultze A. Izbicki J.R. Bokemeyer C. et al.ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.Cell. Signal. 2015; 27: 373-381Crossref PubMed Scopus (44) Google Scholar and that, when mutated, can result in a common type of primary brain tumor (meningioma).20Clark V.E. Erson-Omay E.Z. Serin A. Yin J. Cotney J. Ozduman K. Avşar T. Li J. Murray P.B. Henegariu O. et al.Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.Science. 2013; 339: 1077-1080Crossref PubMed Scopus (556) Google Scholar A third was discovered on chromosome 11q and included the Shh and/or WNT pathway members WNT11 (MIM: 603699) and LRP5 (MIM: 603506). The WNT pathway has parallel roles during development to the Shh signaling pathway21Ulloa F. Martí E. Wnt won the war: antagonistic role of Wnt over Shh controls dorso-ventral patterning of the vertebrate neural tube.Dev. Dyn. 2010; 239: 69-76PubMed Google Scholar and is also critical for axon guidance.22Zou Y. Wnt signaling in axon guidance.Trends Neurosci. 2004; 27: 528-532Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar A simulation analysis to assess the probability of observing this number of Shh genes in randomly selected (see Supplemental Note), similarly sized CNV or LOH events throughout the genome was significant (p = 0.046). We also performed a simulation analysis for the salivary secretion pathway but did not observe a significant enrichment for genes in this pathway (p = 0.716). Given the preponderance of candidate somatic mutations in Shh genes, we then performed TRS of 50 genes in the Shh signaling pathway, as defined by KEGG,18Kanehisa M. Goto S. KEGG: kyoto encyclopedia of genes and genomes.Nucleic Acids Res. 2000; 28: 27-30Crossref PubMed Scopus (18116) Google Scholar as well as of the transcriptional coactivator, CREBBP, in 15 individuals with HH to further screen for candidate causal mutations (see Supplemental Note for further methodological details). This analysis revealed somatic mutations in two additional individuals, both nonsense mutations in GLI3, confirmed by Sanger sequencing (Table 1). It is noteworthy that two of eight mutations in GLI3 and PRKACA detected by WES or TRS were present in a small fraction of sequencing reads from leukocyte-derived DNA, albeit a much smaller fraction than in tumors, and not confirmed to be present with another genotyping method (Table 1). This suggests that the mutations might be diffusely expressed in the brain, rather than just in the hamartoma per se. This is consistent with the observation of germline mutations in GLI3 in Pallister-Hall syndrome, in which HH is usually the only lesion in the brain.9Kang S. Graham Jr., J.M. Olney A.H. Biesecker L.G. GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome.Nat. Genet. 1997; 15: 266-268Crossref PubMed Scopus (407) Google Scholar Although the biological significance of the observed enrichment of candidate variants in the salivary secretion pathway genes in HH is unclear, we did not further pursue these variants given that we detected no enrichment of genes in this pathway in somatic CNVs. Additionally, we note that Saitsu et al., who also recently screened for somatic mutations in HH, further support the association of the Shh pathway with HH with their work and did not report somatic mutations in the salivary secretion pathway genes.12Saitsu H. Sonoda M. Higashijima T. Shirozu H. Masuda H. Tohyama J. Kato M. Nakashima M. Tsurusaki Y. Mizuguchi T. et al.Somatic mutations in GLI3 and OFD1 involved in sonic hedgehog signaling cause hypothalamic hamartoma.Ann Clin Transl Neurol Epub. 2016; (Mar 24th)Google Scholar We predict that the somatic mutations in the pathway could lead to reduced Shh signaling. GLI3 can act as both a transcriptional activator and repressor of downstream targets.23Dai P. Akimaru H. Tanaka Y. Maekawa T. Nakafuku M. Ishii S. Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3.J. Biol. Chem. 1999; 274: 8143-8152Crossref PubMed Scopus (442) Google Scholar In the absence of Shh, protein kinase A (PKA) phosphorylates GLI3, causing its cleavage into a repressor form of the protein (Figure 123Dai P. Akimaru H. Tanaka Y. Maekawa T. Nakafuku M. Ishii S. Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3.J. Biol. Chem. 1999; 274: 8143-8152Crossref PubMed Scopus (442) Google Scholar). This repressor then translocates to the nucleus and suppresses transcription of target genes. The somatic mutations we discovered in GLI3 all occurred in the same region as germline mutations in Pallister-Hall syndrome. The mutant, truncated protein in Pallister-Hall syndrome has been shown to localize to the nucleus and repress expression of target genes, leading to less Shh signaling.24Shin S.H. Kogerman P. Lindström E. Toftgárd R. Biesecker L.G. GLI3 mutations in human disorders mimic Drosophila cubitus interruptus protein functions and localization.Proc. Natl. Acad. Sci. USA. 1999; 96: 2880-2884Crossref PubMed Scopus (141) Google Scholar Two of three confirmed PRKACA mutations were located in the C-terminal region of the catalytic subunit; these truncating mutations could impair binding of the regulatory subunit of PKA, leading to a constitutively active form of the protein and subsequent repression of target genes due to increased phosphorylation and cleavage of GLI3. Interestingly, in adrenocortical tumors, a recurrent somatic mutation (encoding p.Leu206Arg) in PRKACA has been shown to inhibit binding of the regulatory subunit of PKA, leading to constitutive activation of the catalytic subunit of PKA and increased phosphorylation activity.25Goh G. Scholl U.I. Healy J.M. Choi M. Prasad M.L. Nelson-Williams C. Kunstman J.W. Korah R. Suttorp A.C. Dietrich D. et al.Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors.Nat. Genet. 2014; 46: 613-617Crossref PubMed Scopus (181) Google Scholar, 26Sato Y. Maekawa S. Ishii R. Sanada M. Morikawa T. Shiraishi Y. Yoshida K. Nagata Y. Sato-Otsubo A. Yoshizato T. et al.Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome.Science. 2014; 344: 917-920Crossref PubMed Scopus (153) Google Scholar In summary, this comprehensive analysis revealed 14 somatic mutations (four nonsense changes, two frameshift indels, one in-frame insertion, and seven large CNV or LOH events; Table 1; Figure 1) in Shh pathway genes. PRKACA is now securely implicated as a HH-associated gene, in addition to the previously associated Shh gene, GLI3.10Wallace R.H. Freeman J.L. Shouri M.R. Izzillo P.A. Rosenfeld J.V. Mulley J.C. Harvey A.S. Berkovic S.F. Somatic mutations in GLI3 can cause hypothalamic hamartoma and gelastic seizures.Neurology. 2008; 70: 653-655Crossref PubMed Scopus (17) Google Scholar, 11Craig D.W. Itty A. Panganiban C. Szelinger S. Kruer M.C. Sekar A. Reiman D. Narayanan V. Stephan D.A. Kerrigan J.F. Identification of somatic chromosomal abnormalities in hypothalamic hamartoma tissue at the GLI3 locus.Am. J. Hum. Genet. 2008; 82: 366-374Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar, 12Saitsu H. Sonoda M. Higashijima T. Shirozu H. Masuda H. Tohyama J. Kato M. Nakashima M. Tsurusaki Y. Mizuguchi T. et al.Somatic mutations in GLI3 and OFD1 involved in sonic hedgehog signaling cause hypothalamic hamartoma.Ann Clin Transl Neurol Epub. 2016; (Mar 24th)Google Scholar An additional fifteen genes (AKT1, BMP4, CREBBP, GLI2, IHH, LRP2, LRP5, SHH, SMO, STK36, WNT2, WNT6, WNT10A, WNT11, and WNT16) associated with the Shh tumor suppressor pathway and the related WNT pathway are potentially implicated, as well as, possibly, other genes (within the large CNV or LOH regions) that do not have an obvious biological link to the Shh pathway. We did not identify somatic mutations in OFD1 (MIM: 300170), a recently reported candidate HH-associated gene identified in a mix of sporadic and syndromic cases from the Japanese population.12Saitsu H. Sonoda M. Higashijima T. Shirozu H. Masuda H. Tohyama J. Kato M. Nakashima M. Tsurusaki Y. Mizuguchi T. et al.Somatic mutations in GLI3 and OFD1 involved in sonic hedgehog signaling cause hypothalamic hamartoma.Ann Clin Transl Neurol Epub. 2016; (Mar 24th)Google Scholar Five cases had “unconfirmed findings” because there was insufficient DNA to complete the validation of all variants detected, whereas for 19 cases, no variants in genes encoding proteins directly or indirectly related to Shh were discovered (Table 2). Thus, we identified potentially pathogenic mutations in the Shh pathway in at least 37% (14/38) of individuals with HH, and possibly as many as 50% (19/38). This aggregation to a particular pathway is reminiscent of the remarkable contribution of various mTOR pathway gene mutations to malformations of cortical development, realized through similar clinico-molecular studies with privileged brain tissue over the last few years.2Poduri A. Evrony G.D. Cai X. Walsh C.A. Somatic mutation, genomic variation, and neurological disease.Science. 2013; 341: 1237758Crossref PubMed Scopus (407) Google Scholar, 3Lee J.H. Huynh M. Silhavy J.L. Kim S. Dixon-Salazar T. Heiberg A. Scott E. Bafna V. Hill K.J. Collazo A. et al.De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Nat. Genet. 2012; 44: 941-945Crossref PubMed Scopus (491) Google Scholar, 27Jamuar S.S. Walsh C.A. Somatic mutations in cerebral cortical malformations.N. Engl. J. Med. 2014; 371: 2038Crossref PubMed Scopus (236) Google Scholar The intense interest in Shh signaling in a variety of cancers has led to the development of potentially therapeutic agents acting on this pathway that could also be explored in treating this syndrome.28Scales S.J. de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.Trends Pharmacol. Sci. 2009; 30: 303-312Abstract Full Text Full Text PDF PubMed Scopus (571) Google Scholar, 29Sheikh A. Alvi A.A. Aslam H.M. Haseeb A. Hedgehog pathway inhibitors - current status and future prospects.Infect. Agent. Cancer. 2012; 7: 29Crossref PubMed Scopus (18) Google ScholarTable 2Study Participants with No Candidate or Unconfirmed Candidate Somatic Mutations in or Linked to the Shh PathwaySubjectGenomic Analysis Method(s)Annotation of Candidate MutationsShh Gene(s) (KEGG)VAF BrainVAF BloodMethod of DetectionWESCMATRShht929×××c.494dupG (p.Cys168LeufsTer4) [GenBank: NM_057168.1]WNT16aCandidate mutation found in WNT16 was detected with both next-generation sequencing technologies but not confirmed with Sanger sequencing because of insufficient DNA.31%4%WES, TRShht25093 g×−−c.248T>C (p.Leu83Pro) [GenBank: NM_002730.3]PRKACA14%1%WEShht20138−××c.984dupT (p.Asp329Ter) [GenBank: NM_002730.3]PRKACA25%0%TRShht25060−××c.1025dupG (p.Ala343ArgfsTer35) [GenBank: NM_003393.3]WNT8B28%0%TRSc.394C>T (p.Gln132Ter) [GenBank: NM_182948.2]PRKACB25%0%c.5293dupC (p.Gln1765ProfsTer201) [GenBank: NM_004380.2]CREBBPbTranscriptional regulator of the Shh pathway.14%0%hht25186−−×c.6858dupT (p.Glu2287Ter) [GenBank: NM_004525.2]LRP217%3%TRSc.4230dupT (p.Gly1411TrpfsTer10) [GenBank: NM_004380.2]CREBBPbTranscriptional regulator of the Shh pathway.14%0%hht25064−−×NDNANANAhht1276d×−−NDNANANAhht322b××−NDNANANAhht25132h××−NDNANANAhht786×××NDNANANAhht25080×××NDNANANAhht25099×××NDNANANAhht25059−××NDNANANAhht25082×−×NDNANANAhht25050−×−NDNANANAhht25054−×−NDNANANAhht25066−×−NDNANANAhht25072−×−NDNANANAhht25079−×−NDNANANAhht25089−×−NDNANANAhht25097−×−NDNANANAhht25098−×−NDNANANAhht25052−××NDNANANAhht25056−××NDNANANAShh, Sonic hedgehog; VAF, variant allele frequency; WES, whole-exome sequencing; CMA, chromosomal microarray; TRS, targeted resequencing; ×, used; −, not used; NA, not applicable; ND, none detected. All coordinates correspond to the UCSC Genome Browser reference genome (GRCH37/hg19).a Candidate mutation found in WNT16 was detected with both next-generation sequencing technologies but not confirmed with Sanger sequencing because of insufficient DNA.b Transcriptional regulator of the Shh pathway. Open table in a new tab Shh, Sonic hedgehog; VAF, variant allele frequency; WES, whole-exome sequencing; CMA, chromosomal microarray; TRS, targeted resequencing; ×, used; −, not used; NA, not applicable; ND, none detected. All coordinates correspond to the UCSC Genome Browser reference genome (GRCH37/hg19). I.E.S. discloses payments from UCB Pharma and Athena Diagnostics and Transgenomics for lectures and educational presentations. D.B.G. is an equity holder in Pairnomix, a company focused on modeling epilepsy mutations. S.F.B. discloses payments from UCB Pharma, Novartis Pharmaceuticals, Sanofi-Aventis, and Jansen Cilag for lectures and educational presentations and a patent for SCN1A testing held by Bionomics Inc. and licensed to various diagnostic companies. We thank the families for their participation in this study, and we value the advocacy from the Hope for Hypothalamic Hamartoma Foundation (http://hopeforhh.org). Elena Aleksoska (Epilepsy Research Centre) performed genomic DNA extractions from tissues. Brett Copeland, Joshua Bridgers, and Sitharthan Kamalakaran (Institute for Genomic Medicine) provided bioinformatics support. Dr. Paul Lockhart, Greta Gillies, and Kate Pope (Murdoch Childrens Research Institute) assisted with collection of tissue, and Jeffrey Rosenfeld and Wirginia Maixner (Royal Children’s Hospital, Melbourne) performed surgeries. This study was supported by a National Health and Medical Research Council (NHMRC) Program Grant (628952) to S.F.B. and I.E.S., a Practitioner Fellowship (1006110) to I.E.S, and a Career Development Fellowship (1063799) to M.S.H. I.E.S. was also funded by grants from the NIH, Australian Research Council, Health Research Council of New Zealand, CURE, American Epilepsy Society, US Department of Defense Autism Spectrum Disorder Research Program, March of Dimes, and Perpetual Charitable Trustees. E.L.H. was supported by a NIH grant (R21-NS078657). N.C.J. was supported by an Australian Research Council Future Fellowship (13100100). Acknowledgments of individuals and funding sources responsible for the samples used in this study as controls are provided in the Supplemental Data. Download .pdf (.38 MB) Help with pdf files Document S1. Supplemental Note, Figures S1 and S2, Tables S1 and S2, and Acknowledgments Download .xlsx (.04 MB) Help with xlsx files Table S3. Candidate Somatic Variants Called from WES and TRS of Paired Harmatoma-Leukocyte DNA Samples from Individuals with HH Consensus Coding Sequence, https://www.ncbi.nlm.nih.gov/CCDS/ExAC Browser, http://exac.broadinstitute.org/GenBank, http://www.ncbi.nlm.nih.gov/genbank/Ingenuity Pathway Analysis, http://www.qiagen.com/ingenuityKyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/NCBI Gene, http://www.ncbi.nlm.nih.gov/geneNHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/OMIM, http://www.omim.org/UCSC Genome Browser, http://genome.ucsc.eduVariant Effect Predictor, http://useast.ensembl.org/Homo_sapiens/Tools/VEP" @default.
• W2489722909 created "2016-08-23" @default.
• W2489722909 creator A5004461693 @default.
• W2489722909 creator A5016479884 @default.
• W2489722909 creator A5024558351 @default.
• W2489722909 creator A5025028778 @default.
• W2489722909 creator A5026198048 @default.
• W2489722909 creator A5028913352 @default.
• W2489722909 creator A5030791987 @default.
• W2489722909 creator A5041159807 @default.
• W2489722909 creator A5041523170 @default.
• W2489722909 creator A5042789080 @default.
• W2489722909 creator A5044649471 @default.
• W2489722909 creator A5044685689 @default.
• W2489722909 creator A5051005074 @default.
• W2489722909 creator A5054067653 @default.
• W2489722909 creator A5056695807 @default.
• W2489722909 creator A5061379662 @default.
• W2489722909 creator A5062870293 @default.
• W2489722909 creator A5075793305 @default.
• W2489722909 creator A5088328886 @default.
• W2489722909 date "2016-08-01" @default.
• W2489722909 modified "2023-10-14" @default.
• W2489722909 title "Mutations of the Sonic Hedgehog Pathway Underlie Hypothalamic Hamartoma with Gelastic Epilepsy" @default.
• W2489722909 cites W1483653355 @default.
• W2489722909 cites W1742756123 @default.
• W2489722909 cites W1749057191 @default.
• W2489722909 cites W1964350908 @default.
• W2489722909 cites W1964444860 @default.
• W2489722909 cites W1983145618 @default.
• W2489722909 cites W1987182404 @default.
• W2489722909 cites W1992384218 @default.
• W2489722909 cites W1999773100 @default.
• W2489722909 cites W2000381516 @default.
• W2489722909 cites W2013482405 @default.
• W2489722909 cites W2024412209 @default.
• W2489722909 cites W2025963445 @default.
• W2489722909 cites W2048167482 @default.
• W2489722909 cites W2048851591 @default.
• W2489722909 cites W2079701909 @default.
• W2489722909 cites W2086289230 @default.
• W2489722909 cites W2090542192 @default.
• W2489722909 cites W2093838693 @default.
• W2489722909 cites W2120282622 @default.
• W2489722909 cites W2128200231 @default.
• W2489722909 cites W2138601221 @default.
• W2489722909 cites W2145074684 @default.
• W2489722909 cites W2155943701 @default.
• W2489722909 cites W2171632390 @default.
• W2489722909 cites W2307164172 @default.
• W2489722909 cites W4294216483 @default.
• W2489722909 doi "https://doi.org/10.1016/j.ajhg.2016.05.031" @default.
• W2489722909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4974069" @default.
• W2489722909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27453577" @default.
• W2489722909 hasPublicationYear "2016" @default.
• W2489722909 type Work @default.
• W2489722909 sameAs 2489722909 @default.
• W2489722909 citedByCount "52" @default.
• W2489722909 countsByYear W24897229092017 @default.
• W2489722909 countsByYear W24897229092018 @default.
• W2489722909 countsByYear W24897229092019 @default.
• W2489722909 countsByYear W24897229092020 @default.
• W2489722909 countsByYear W24897229092021 @default.
• W2489722909 countsByYear W24897229092022 @default.
• W2489722909 countsByYear W24897229092023 @default.
• W2489722909 crossrefType "journal-article" @default.
• W2489722909 hasAuthorship W2489722909A5004461693 @default.
• W2489722909 hasAuthorship W2489722909A5016479884 @default.
• W2489722909 hasAuthorship W2489722909A5024558351 @default.
• W2489722909 hasAuthorship W2489722909A5025028778 @default.
• W2489722909 hasAuthorship W2489722909A5026198048 @default.
• W2489722909 hasAuthorship W2489722909A5028913352 @default.
• W2489722909 hasAuthorship W2489722909A5030791987 @default.
• W2489722909 hasAuthorship W2489722909A5041159807 @default.
• W2489722909 hasAuthorship W2489722909A5041523170 @default.
• W2489722909 hasAuthorship W2489722909A5042789080 @default.
• W2489722909 hasAuthorship W2489722909A5044649471 @default.
• W2489722909 hasAuthorship W2489722909A5044685689 @default.
• W2489722909 hasAuthorship W2489722909A5051005074 @default.
• W2489722909 hasAuthorship W2489722909A5054067653 @default.
• W2489722909 hasAuthorship W2489722909A5056695807 @default.
• W2489722909 hasAuthorship W2489722909A5061379662 @default.
• W2489722909 hasAuthorship W2489722909A5062870293 @default.
• W2489722909 hasAuthorship W2489722909A5075793305 @default.
• W2489722909 hasAuthorship W2489722909A5088328886 @default.
• W2489722909 hasBestOaLocation W24897229091 @default.
• W2489722909 hasConcept C134018914 @default.
• W2489722909 hasConcept C169760540 @default.
• W2489722909 hasConcept C2775932916 @default.
• W2489722909 hasConcept C2776637008 @default.
• W2489722909 hasConcept C2778186239 @default.
• W2489722909 hasConcept C2778367240 @default.
• W2489722909 hasConcept C2778539099 @default.
• W2489722909 hasConcept C2779449703 @default.
• W2489722909 hasConcept C2908900992 @default.
• W2489722909 hasConcept C54355233 @default.
• W2489722909 hasConcept C62478195 @default.
• W2489722909 hasConcept C71315377 @default.

• next